GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Other Current Receivables

Nyrada (ASX:NYR) Other Current Receivables : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Other Current Receivables?

Nyrada's Other Current Receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Nyrada's annual Other Current Receivables increased from Jun. 2021 (A$0.00 Mil) to Jun. 2022 (A$0.02 Mil) and increased from Jun. 2022 (A$0.02 Mil) to Jun. 2023 (A$0.03 Mil).


Nyrada Other Current Receivables Historical Data

The historical data trend for Nyrada's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Other Current Receivables Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Other Current Receivables
- - - 0.02 0.03

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Receivables Get a 7-Day Free Trial - 0.02 - 0.03 -

Nyrada Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Nyrada Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Nyrada's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Nyrada (ASX:NYR) Business Description

Industry
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines